Eliza Sudbury
Nurse Practitioner · Muskegon, MINPI 1023407640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 635 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $14.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$872
- Otsuka America Pharmaceutical, Inc.$543
- Neurocrine Biosciences, Inc.$528
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,907100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 87 | $1,392 |
| AbbVie | 115 | $1,361 |
| Supernus Pharmaceuticals, Inc. | 107 | $1,104 |
| Teva Pharmaceuticals USA, Inc. | 81 | $872 |
| Otsuka America Pharmaceutical, Inc. | 25 | $543 |
| Neurocrine Biosciences, Inc. | 29 | $528 |
| Alkermes, Inc. | 23 | $460 |
| Corium, LLC | 41 | $407 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $258 |
| Vanda Pharmaceuticals Inc. | 14 | $236 |
| E.r. Squibb & Sons, L.L.C. | 10 | $217 |
| Lundbeck LLC | 11 | $207 |
| Boehringer Ingelheim | 9 | $166 |
| Axsome Therapeutics, Inc. | 7 | $158 |
| Novo Nordisk | 7 | $120 |
| Lilly USA, LLC | 7 | $119 |
| Indivior Inc. | 7 | $105 |
| Johnson & Johnson | 5 | $89 |
| Ironwood Pharmaceuticals, Inc | 4 | $87 |
| Sunovion Pharmaceuticals Inc. | 5 | $73 |
| Tris Pharma Inc | 4 | $70 |
| Philips North America LLC | 3 | $56 |
| Bayer | 3 | $48 |
| Amgen | 3 | $41 |
| Nestle Healthcare Nutrition Inc. | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Eisai Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| AstraZeneca | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$125
How this compares
$8,927 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 26 | $30,142 |
| RexultiBrexpiprazole | 18 | $24,752 |
| TrintellixVortioxetine Hydrobromide | 15 | $10,954 |
| Lisdexamfetamine Dimesylate | 13 | $2,431 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $1,764 |
| Oxcarbazepine | 28 | $1,543 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $1,155 |
| Paliperidone ErPaliperidone | 12 | $697 |
| Buspirone Hcl | 25 | $425 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $386 |
| Trazodone Hcl | 18 | $193 |
| Hydroxyzine Pamoate | 16 | $179 |
| Lamotrigine | 22 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $158 | $30,14226 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $543 | $24,75218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $258 | $10,95415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Muskegon
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.